Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNRX Quoin Pharmaceuticals

Post-Market Trading 05-09 16:07:58 EDT

0.7950

+0.0086

+1.09%

High0.8100	Low0.7550	Vol45.04K
Open0.8000	D1 Closing0.7864	Amplitude6.99%
Mkt Cap2.93M	Tradable Cap2.91M	Total Shares3.69M
T/O35.46K	T/O Rate1.23%	Tradable Shares3.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"QNRX","market":"US","secType":"STK","nameCN":"Quoin Pharmaceuticals","latestPrice":0.795,"timestamp":1715284799999,"preClose":0.7864,"halted":0,"volume":45043,"delay":0,"floatShares":3666269,"shares":3685970,"eps":-9.639976,"marketStatus":"Post-Market Trading","change":0.0086,"latestTime":"05-09 16:07:58 EDT","open":0.8,"high":0.81,"low":0.755,"amount":35462.939459,"amplitude":0.069939,"askPrice":0.82,"askSize":110,"bidPrice":0.72,"bidSize":195,"shortable":3,"etf":0,"ttmEps":-9.639976,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1715299200000},"marketStatusCode":4,"adr":0,"adrRate":1,"exchange":"NASDAQ","adjPreClose":0.7864,"preHourTrading":{"tag":"盘前","latestPrice":0.8058,"preClose":0.7864,"latestTime":"09:15 EDT","volume":510,"amount":418.61952599999995,"timestamp":1715260556852},"volumeRatio":0.912655},"requestUrl":"/m/hq/s/QNRX","defaultTab":"news","newsList":[{"id":"2434019961","title":"Quoin Pharmaceuticals Non-GAAP EPS of -$1.11 misses by $0.70","url":"https://stock-news.laohu8.com/highlight/detail?id=2434019961","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434019961?lang=en_us&edition=fundamental","pubTime":"2024-05-09 22:51","pubTimestamp":1715266312,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals press release  (NASDAQ:QNRX): Q1  Non-GAAP EPS of -$1.11  misses by $0.70.\nCash and cash equivalents of $1.83M","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4103785-quoin-pharmaceuticals-non-gaap-eps-of-1_11-misses-0_70","is_publish_highlight":false,"gpt_icon":0},{"id":"2434942250","title":"Quoin Pharmaceuticals Q1 EPS $(1.11) Compared With $(4.09) YoY, Quoin Had Approximately $14.7M In Cash & Equivalents As Of March 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2434942250","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434942250?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:36","pubTimestamp":1715258172,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.76) by 46.05 percent. This is a 72.79 percent increase over losses of $(4.08) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38730181/quoin-pharmaceuticals-q1-eps-1-11-compared-with-4-09-yoy-quoin-had-approximately-14-7m-in-cash-equi","is_publish_highlight":false,"gpt_icon":0},{"id":"2434809443","title":"Press Release: Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2434809443","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434809443?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:30","pubTimestamp":1715257800,"startTime":"0","endTime":"0","summary":"FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies. U.S. and International patent filed for novel Netherton Syndrome combination product. ASHBURN, Va., May 09, 2024  -- Quoin Pharmaceuticals Ltd.  , a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the first quarter ended March 31, 2024.During the quarter, we expanded our intellectual property portfolio by the filing of US and International patent applications for a novel combination product as a treatment for Netherton Syndrome. We continue to explore additional patent opportunities for the product in both clinical and in the manufacturing of the active ingredient and finished product. Finally, via the combination of a successful public offering and the execution of an equity line of credit arrangement, we have extended our cash runway into late ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432568339","title":"Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432568339","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432568339?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:10","pubTimestamp":1714680600,"startTime":"0","endTime":"0","summary":"ASHBURN, Va., May 02, 2024  -- Quoin Pharmaceuticals Ltd.  , a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024.The announcement will provide an operational update regarding the company’s achievements during the quarter, and will detail financial highlights.For further information, contact:Investor RelationsPCG AdvisoryJeff Ramsonjramson@pcgadvisory.com 863-6341","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RnVbzAeH3fAA0IdxS31DCA--~B/aD03Njg7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/06790a224a8bf4eaff6ec2d82577b006","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RnVbzAeH3fAA0IdxS31DCA--~B/aD03Njg7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/06790a224a8bf4eaff6ec2d82577b006"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quoin-pharmaceuticals-announce-first-quarter-201000824.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420927218","title":"Maxim Group Lowers Quoin Pharmaceuticals (NASDAQ:QNRX) Price Target to $4.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2420927218","media":"Defense World","top":-1,"share":"https://ttm.financial/m/news/2420927218?lang=en_us&edition=fundamental","pubTime":"2024-03-19 15:19","pubTimestamp":1710832774,"startTime":"0","endTime":"0","summary":"Maxim Group Lowers Quoin Pharmaceuticals (NASDAQ:QNRX) Price Target to $4.00","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMidWh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8xOS9tYXhpbS1ncm91cC1sb3dlcnMtcXVvaW4tcGhhcm1hY2V1dGljYWxzLW5hc2RhcXFucngtcHJpY2UtdGFyZ2V0LXRvLTQtMDAuaHRtbNIBAA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMidWh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8xOS9tYXhpbS1ncm91cC1sb3dlcnMtcXVvaW4tcGhhcm1hY2V1dGljYWxzLW5hc2RhcXFucngtcHJpY2UtdGFyZ2V0LXRvLTQtMDAuaHRtbNIBAA?oc=5","is_publish_highlight":false,"gpt_icon":0},{"id":"2419098669","title":"Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2419098669","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2419098669?lang=en_us&edition=fundamental","pubTime":"2024-03-15 22:52","pubTimestamp":1710514344,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals, Ltd.  Q4 2023 Earnings Call Transcript March 14, 2024 Quoin Pharmaceuticals, Ltd. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (. Michael Myers: Thank you, Gordon. Good morning, everyone, and welcome to today's call. We are pleased to have the opportunity to report on Quoin's progress in the past quarter and throughout the year as a whole. 2023 was quite simply a truly transformational year for Quoin. During that year, we released the first ever clinical data generated from a trial in Netherton syndrome subjects being conducted under an open investigational new drug application or IND with the US FDA. This was a significant and important milestone not just for Quoin, but for a Netherton community as a whole. I'm pleased to say that this initial data was encouraging and overall positive across a number of clinical end points. And crucially, there was also a complete absence of any safety signals whatsoever.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FFaBPL1eaigW79ufzxNAnw--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/574cbf5dae29b07a4f01a4ebfe9ab7c2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FFaBPL1eaigW79ufzxNAnw--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/574cbf5dae29b07a4f01a4ebfe9ab7c2"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quoin-pharmaceuticals-ltd-nasdaq-qnrx-145224062.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419657136","title":"Quoin Pharmaceuticals Q4 2023 GAAP EPS $(2.08) Beats $(2.31) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2419657136","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2419657136?lang=en_us&edition=fundamental","pubTime":"2024-03-14 04:13","pubTimestamp":1710360792,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(2.08) per share which beat the analyst consensus estimate of $(2.31) by 9.96 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37675993/quoin-pharmaceuticals-q4-2023-gaap-eps-2-08-beats-2-31-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2419657938","title":"Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2419657938","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2419657938?lang=en_us&edition=fundamental","pubTime":"2024-03-13 20:05","pubTimestamp":1710331500,"startTime":"0","endTime":"0","summary":"Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/13/2845843/0/en/Quoin-Pharmaceuticals-Provides-Corporate-Update-and-Announces-Fourth-Quarter-and-2023-Financial-Results.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417805163","title":"Samsara, DocuSign, Gap among premarket gainers' pack","url":"https://stock-news.laohu8.com/highlight/detail?id=2417805163","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2417805163?lang=en_us&edition=fundamental","pubTime":"2024-03-08 21:30","pubTimestamp":1709904606,"startTime":"0","endTime":"0","summary":"Ainos  +147%. Psyence Biomedical  +104%. CERo Therapeutics  +47%. Gulf Island Fabrication  +27% on Q4 earnings release. Recruiter.com  +17%. Porch Group  +20% on Q4 earnings release. reAlpha Tech  +18%. Grifols  +17% as auditor clears annual accounts. Quoin Pharmaceuticals  +18%.  Ucommune International  +11%. Samsara  +13% on Q4 earnings release. Ocean Biomedical  +13%. SU Group  +11%. Smith & Wesson Brands  +11% on Q3 earnings release. Treasure Global  +12% after Treasure Global’s AI-powered ZCITY premium store surpasses expectations. Swvl Holdings  +9%. DocuSign  +9% following its upbeat 4Q24 results  QuantaSing Group  +9%. Funko  +8% on Q4 earnings release. Gap  +8% on Q4 earnings release. SoundHound  7%. Regenxbio  7%. SciSparc  6% after FDA status for LSD formulation; announces enrollment of first patient for its clinical trial for children with autism spectrum disorder. See the biggest morning stock movers.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4077614-samsara-docusign-gap-among-premarket-gainers-pack","is_publish_highlight":false,"gpt_icon":0},{"id":"2417257478","title":"ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417257478","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2417257478?lang=en_us&edition=fundamental","pubTime":"2024-03-06 05:38","pubTimestamp":1709674680,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones Newswires using technology from Automated Insights.International stocks trading in New York closed lower on Tuesday as the S&P/BNY Mellon index of American depositary receipts declined 0.7% to 174.34.The European index dropped 0.6% to 167.51. The Asian index dropped 0.7% to 206.02. The Latin American index declined 0.7% to 213.94, while the emerging-markets index dropped 1.4% to 325.46.Quoin Pharmaceuticals Ltd., based in Israel, posted the largest decline, plummeting 48.3% to $1.50, followed by shares of China's AirNet Technology Inc., which plunged 18.7% to $1.15. Shares of U.K.-based Argo Blockchain PLC tumbled 18.6% to $1.79.China's Phoenix New Media Ltd. Cl A was the biggest leader during the session, rocketing 46.2% to $2.00. France-based PHAXIAM Therapeutics S.A. soared 20.4% to $3.01. Fresenius Medical Care AG, which is based in Germany, rounded out the top three leaders, with shares jumping 11.2% to $20.76.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2417042176","title":"QNRX: Potential Pool of Study Participants Expands; Financial Position Strengths","url":"https://stock-news.laohu8.com/highlight/detail?id=2417042176","media":"Zacks Small Cap Research","top":-1,"share":"https://ttm.financial/m/news/2417042176?lang=en_us&edition=fundamental","pubTime":"2024-03-05 23:12","pubTimestamp":1709651520,"startTime":"0","endTime":"0","summary":"Strengthening financial position to advance clinical studies…Quoin Pharmaceuticals  has completed a capital raise to strengthen its financial position in order to continue to move lead asset QRX003 and other candidates in its portfolio forward. As Quoin advances clinical studies to evaluate QRX003 for the treatment of Netherton Syndrome , the offering enhances the company’s financial flexibility to move forward on several fronts. The company has two active NS studies that are being conducted concurrently and recently received FDA clearance to recruit teenage subjects into both clinical studies. In fact, Quoin believes it is the only development company conducting dual NS studies concurrently under an open IND application. Both trials utilize the same investigators and clinical sites, which Quoin expects will result in substantial operational synergies and cost savings.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HGEhZmWGKkyBknyBBKLOrw--~B/aD01NTY7dz0xMjQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/6caaac5ed82469923baf944bc603f08e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HGEhZmWGKkyBknyBBKLOrw--~B/aD01NTY7dz0xMjQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/6caaac5ed82469923baf944bc603f08e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qnrx-potential-pool-study-participants-151200495.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417417534","title":"Dow Dips Over 100 Points; Target Posts Upbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2417417534","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2417417534?lang=en_us&edition=fundamental","pubTime":"2024-03-05 23:01","pubTimestamp":1709650910,"startTime":"0","endTime":"0","summary":"U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Tuesday.\n\nFollowing the market opening Tuesday, the Dow traded down 0.33% to 38,861.95 while the NASDAQ fell 0.82% to 16,074.48. The S&amp;P 500 also fell, dropping, 0.42% to 5,109.27.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37484810/dow-dips-over-100-points-target-posts-upbeat-earnings","is_publish_highlight":false,"gpt_icon":0},{"id":"2417883171","title":"Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2417883171","media":"TradingView","top":-1,"share":"https://ttm.financial/m/news/2417883171?lang=en_us&edition=fundamental","pubTime":"2024-03-05 04:02","pubTimestamp":1709582547,"startTime":"0","endTime":"0","summary":"Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMiemh0dHBzOi8vd3d3LnRyYWRpbmd2aWV3LmNvbS9uZXdzL2JlbnppbmdhOmQwOGVkYTcwMDA5NGI6MC1jcnVkZS1vaWwtZG93bi1vdmVyLTEtcXVvaW4tcGhhcm1hY2V1dGljYWxzLXNoYXJlcy1zcGlrZS1oaWdoZXIv0gEA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMiemh0dHBzOi8vd3d3LnRyYWRpbmd2aWV3LmNvbS9uZXdzL2JlbnppbmdhOmQwOGVkYTcwMDA5NGI6MC1jcnVkZS1vaWwtZG93bi1vdmVyLTEtcXVvaW4tcGhhcm1hY2V1dGljYWxzLXNoYXJlcy1zcGlrZS1oaWdoZXIv0gEA?oc=5","is_publish_highlight":false,"gpt_icon":0},{"id":"2416123744","title":"Quoin stock soars 60% on FDA update for ichthyosis drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2416123744","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2416123744?lang=en_us&edition=fundamental","pubTime":"2024-03-04 23:37","pubTimestamp":1709566654,"startTime":"0","endTime":"0","summary":"Shares of Quoin Pharmaceuticals  soared 60% in morning trading Monday on news that the FDA has cleared the company to include teenagers in two clinicals trials for its drug QRX003 in the treatment of Netherton syndrome, a form of skin disorder ichthyosis. The biotech company said the agency has cleared it to recruit teenagers aged 14 and up to participate in the ongoing trials, which should significantly expand the number of eligible subjects and could lead to a more robust data set. QRX003 is in Phase 3 testing for Netherton syndrome, according to Quoin’s website.  More on Quoin Pharmaceuticals  Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical earnings data for Quoin Pharmaceuticals Financial information for Quoin Pharmaceuticals","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4075322-quoin-stock-soars-on-fda-update-for-ichthyosis-drug","is_publish_highlight":false,"gpt_icon":0},{"id":"2416143522","title":"Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2416143522","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2416143522?lang=en_us&edition=fundamental","pubTime":"2024-03-04 21:21","pubTimestamp":1709558460,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals shares doubled to $6.70 in premarket trading after the company said it received clearance from the U.S. Food and Drug Administration to recruit teen subjects aged 14 years and older into its two ongoing clinical trials for QRX003, which is being developed as a potential treatment for Netherton Syndrome.The specialty pharmaceutical company said both trials are being conducted under Quoin's open Investigational New Drug Application for QRX003.Quoin said this FDA clearance marks the first time that non-adult Netherton subjects will be tested in clinical studies conducted under an open-IND. Teens who are currently receiving off-label systemic therapy will be eligible to participate in the open-label study, while those who are not receiving such therapy may be recruited into the placebo controlled blinded study.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2416148572","title":"Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2416148572","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2416148572?lang=en_us&edition=fundamental","pubTime":"2024-03-04 13:00","pubTimestamp":1709528400,"startTime":"0","endTime":"0","summary":"Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/04/2839532/0/en/Quoin-Pharmaceuticals-Announces-FDA-Clearance-to-Recruit-Teen-Subjects-into-Both-Ongoing-Netherton-Syndrome-Clinical-Studies.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quoinpharma.com","stockEarnings":[{"period":"1week","weight":0.1122},{"period":"1month","weight":0.0126},{"period":"3month","weight":-0.7642},{"period":"6month","weight":-0.7959},{"period":"1year","weight":-0.865},{"period":"ytd","weight":-0.839}],"compareEarnings":[{"period":"1week","weight":0.0337},{"period":"1month","weight":-0.0029},{"period":"3month","weight":0.0379},{"period":"6month","weight":0.1738},{"period":"1year","weight":0.2586},{"period":"ytd","weight":0.0881}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.","exchange":"NASDAQ","name":"Quoin Pharmaceuticals","nameEN":"Quoin Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quoin Pharmaceuticals,QNRX,Quoin Pharmaceuticals股票,Quoin Pharmaceuticals股票老虎,Quoin Pharmaceuticals股票老虎国际,Quoin Pharmaceuticals行情,Quoin Pharmaceuticals股票行情,Quoin Pharmaceuticals股价,Quoin Pharmaceuticals股市,Quoin Pharmaceuticals股票价格,Quoin Pharmaceuticals股票交易,Quoin Pharmaceuticals股票购买,Quoin Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction